EPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
EUPRAXIA PHARMACEUTICALS INC.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 13, 2026
$6.95+0.33 (+4.98%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Eupraxia Pharmaceuticals has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Eupraxia Pharmaceuticals filed with the SEC
Eupraxia Pharmaceuticals Reports Symptom Response Data from its
EX-99.1 to Form 6-K
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
EX-99.3 to Form 6-K
Name and Address of Company
EX-99.1 to Form 6-K
In accordance with Section 11.3 of National Instrument 51-102 – Continuous
EX-99.2 to Form 6-K
TO BE HELD ON JUNE 18, 2026
EX-99.1 to Form 6-K
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
TO ALL APPLICABLE EXCHANGES AND COMMISSIONS:
EX-99.1 to Form 6-K
FOR THE THREE MONTHS ENDED MARCH 31, 2026
EX-99.1 to Form 6-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
EX-99.3 to Form 6-K
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
EX-99.1 to Form 6-K
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
EX-99.1 to Form 6-K
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
EX-99.1 to Form 6-K
TO ALL APPLICABLE EXCHANGES AND COMMISSIONS:
EX-99.1 to Form 6-K
Name and Address of Company
EX-99.1 to Form 6-K
Pre-Funded Warrants to Purchase up to
EX-99.1 to Form 6-K
Eupraxia Pharmaceuticals Announces Proposed Public Offering
EX-99.1 to Form 6-K
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data
EX-99.1 to Form 6-K
For the Three and Nine Months ended September 30, 2025
EX-99.1 to Form 6-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
EX-99.3 to Form 6-K